【作者】 杨东光；

【导师】 孙伟正；

【作者基本信息】 黑龙江中医药大学 ， 中医内科学， 2004， 硕士

【摘要】 本论文在对骨髓增生异常综合征(简称MDS)近年来的治疗和研究进行综述后，对40例MDS-RA患者进行了临床观察研究。以补髓生血颗粒加全反式维甲酸(ATRA)为治疗约物，与ATRA作对照，通过临床疗效总结探讨补髓生血颗粒治疗MDS-RA的机理。 在研究后我们发现，治疗组治疗MDS-RA的有效率为76.19％，优于对照组疗效(42.11％)，两者比较差异显著(P＜0.05)。 治疗组贫血及出血症状明媪改善，二者治疗前后比较差异均显著(P＜0.05)，其改善程度优于对照组。 治疗后，治疗组外周血象明显改善，血红蛋白、白细胞和血小板治疗前后比较差异显著(P＜0.01)，治疗组外周血象改善程度优于对照组。 治疗后，治疗组外周血及骨髓中的幼稚细胞数较疗前均明显降低(P＜0.01)，且其降低程度均优于对照组。 治疗后，治疗组外剧血及骨髓中的病态造血现象较疗前均有改善，治疗前后比较差异显著(P＜0.01)。且其改善程度均优于对照组。 以上结果显示，治疗组可以有效改善MDS-RA的贫血、出血症状及外周血象，降低外周血及骨髓中幼稚细胞数和病态造血现象，其疗效优于对照组，提示补髓生血颗粒是治疗MDS-RA的有效方剂。更多还原

【Abstract】 This thesis paper summarizes the treatment and study on Myelodysplastic Syndrome (abbreviated as MDS) in recent years, then makes a clinical observation and study on 40 Refractory Anemia (abbreviated as RA) patients, using marrow- supplementing and blood-engendering granule plus all-trans retinoic acid as therapeutic medicine, and summarizes therapeutic principle of marrow- supplementing and blood-engendering granule to MDS-RA.After study we find that total MDS-RA therapeutic effect rate in treatment group is 76.19 %, which is superior to that of the controlled group (42.11%), there is significant differences between two groups (P<0.05).After treatment, there is significant improvement of anemia and hemorrhage symptom in treatment group, and compared with that before treatment, the differences is significant (P<0.05), and the improvement degree is superior to that in the controlled group (P<0.05).After treatment, there is significant improvement of peripheral blood in treatment group, and compared with that before treatment, the differences is significant (P<0.01), and the improvement degree is superior to that in the controlled group.After treatment, there is significant discrease of immature cells in peripheral blood and bone marrow in treatment grpup, and compared with that before treatment, the differences is significant (P<0.01), and the improvement degree is superior to tha.t in the controlled group.After treatment, there is significant improvement of morbidgenerating blood phenomenon in both peripheral blood and bone marrow in treatment group, and compared with that before treatment, the differences is significant (P<0.01), and the improvement degree is superior to that in the controlled group (P<0.05).The result above shows marrow-supplementing and blood-engendering granule can effectively improve anemia and hemorrhage symptom and peripheral blood, decrease immature cells in peripheral blood and bone marrow, the degree of which is superior to that in controlled group, and shows marrow-supplementing and blood-engendering granule is an effective prescription for treating MDS-RA.更多还原